제놀루션
Financials
Valuation Metrics
제놀루션's Market Cap is ₩273B. At end of 2025 it was ₩364B. Ranked #2157 of 2,421 in KR market (top 89%), #1400 of 1,640 on KOSDAQ (top 85%), #217 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 27.35B KRW | KR#2,157/2,421 Sec#217/231 |
| Revenue | 10.03B KRW | KR#2,290/2,421 Sec#178/231 |
| Net Income | -5.65B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 94.61B KRW | KR#1,825/2,421 Sec#144/231 |
| Net Assets | 68.83B KRW | KR#1,693/2,421 Sec#144/231 |
| Employees | 86 | KR#1,757/2,421 Sec#140/231 |
| Value | ||
| P/B | 0.40x | KR#564/2,421 Sec#18/231 |
| P/S | 2.73x | KR#1,948/2,421 Sec#116/231 |
| FCF Yield | -26.71% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -8.21% | KR#1,895/2,421 Sec#138/231 |
| ROA | -5.97% | KR#1,975/2,421 Sec#145/231 |
| Op. Margin | -74.15% | KR#2,276/2,421 Sec#166/231 |
| Revenue Growth | 14.42% | KR#714/2,421 Sec#69/231 |
| Financial Health | ||
| Debt Ratio | 37.46% | KR#738/2,421 Sec#89/231 |
| Total Debt | 9.00B KRW | KR#1,657/2,421 Sec#150/231 |
| FCF | -7.31B KRW | KR#1,608/2,421 Sec#134/231 |
| Cash | 18.65B KRW | KR#1,284/2,421 Sec#96/231 |
| Current Ratio | 1.29x | KR#1,412/2,421 Sec#147/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -41.96% | KR#1,883/2,421 Sec#160/231 |
| 1M Return | 2.96% | KR#930/2,421 Sec#66/231 |
| From 52W High | -45.71% | KR#1,199/2,421 Sec#89/231 |
| 1Y MDD | -59.45% | KR#1,446/2,421 Sec#114/231 |
| Trading | ||
| Volume | 44,428 shares | KR#1,187/2,421 Sec#118/231 |
| Trading Value | 62.8M KRW | KR#1,757/2,421 Sec#179/231 |
| Foreign Own. | 1.16% | KR#1,965/2,421 Sec#193/231 |
| Per Share | ||
| EPS | -294 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,587 KRW | KR#1,740/2,421 Sec#128/231 |
Company Info
The company, established in 2006, commenced manufacturing biological products and was listed on KOSDAQ in 2020. It operates in two main sectors: precision medicine, selling nucleic acid extraction reagents and automated equipment, and green bio, developing animal pharmaceuticals and crop protection agents using RNA interference technology. In 2024, it received approval for Honeyguard-R Solution, the world's first gene therapy for honeybee Sacbrood disease. The company is further expanding its business through R&D for Nosema disease treatments and eco-friendly RNA pesticides. Genolution is headquartered in Gangseo-gu, Seoul Metropolitan City.